title: Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis.
abstract: BACKGROUND
  In our previous studies we demonstrated that CXC chemokine receptor 3 (CXCR3) participates in the regulation of lymphocyte trafficking during cecal ligation and puncture (CLP)-induced sepsis. In this study, we evaluated the effects of treatment with anti-CXCR3 immunoglobulin (IgG) and antibiotics on outcome during septic shock caused by CLP.
  
  
  METHODS
  C57BL/6J mice were treated with neutralizing IgG against CXCR3 plus Primaxin either 24 hours prior to, 2 hours after or 6 hours after CLP. Control mice received nonspecific IgG plus Primaxin in the same regimen. Survival, core body temperature, bacterial clearance and systemic cytokine production were evaluated.
  
  
  RESULTS
  Our results show that treatment with anti-CXCR3 IgG plus Primaxin significantly improved survival when administered 24 hours prior to CLP (50% vs. 10%), 2 hours after CLP (55% vs. 10%) or 6 hours after CLP (55% vs. 25%) compared with mice receiving nonspecific IgG plus Primaxin. Treatment with anti-CXCR3 plus Primaxin 24 hours prior to CLP attenuated hypothermia and IL-6 and macrophage inflammatory protein 2 (MIP-2) production but did not alter bacterial clearance. Treatment with anti-CXCR3 IgG and Primaxin 2 hours after CLP did not improve bacterial clearance and systemic cytokine production compared with mice treated with IgG and Primaxin, whereas 6 hours after CLP the bacterial clearance and IL-6 and MIP-2 concentrations, both in plasma and peritoneal lavage fluid, were significantly improved in mice receiving anti-CXCR3 IgG and Primaxin compared with mice that only received nonspecific IgG and Primaxin.
  
  
  CONCLUSIONS
  The results from this study indicate that neutralization of CXCR3 prior to, 2 hours after or 6 hours after the initiation of CLP-induced septic shock improves survival and attenuates CLP-induced inflammation and physiologic dysfunction.
authors.forename: Daniela S
authors.initials: DS
authors.lastname: Herzig
authors.forename: Yin
authors.initials: Y
authors.lastname: Guo
authors.forename: Geping
authors.initials: G
authors.lastname: Fang
authors.forename: Tracy E
authors.initials: TE
authors.lastname: Toliver-Kinsky
authors.forename: Edward R
authors.initials: ER
authors.lastname: Sherwood
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D007074:Immunoglobulin G; D051379:Mice; D008810:Mice, Inbred C57BL; D054367:Receptors, CXCR3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018805:Sepsis / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; C515188:Cxcr3 protein, mouse; D007074:Immunoglobulin G; D054367:Receptors, CXCR3